Elodie Girard

Elodie Girard

Auto-generated profile, based on publicly available information

Elodie Girard

Computational Oncology, PSL Research University, Mines Paris Tech, INSERM U1331 Paris France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
KAK. Rahmani Narj Abadi
K. Rahmani Narj Abadi
CDC. Dupain
C. Dupain
IGI. Guillou
I. Guillou
RSR. Sanchez
R. Sanchez
KNK. Nedara
K. Nedara
Christophe Le TourneauChristophe Le Tourneau
Christophe Le Tourneau
The European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GAs) of patients with recurrent, metastatic, or rare cancer. This study aimed to present outcomes of patients discussed at the molecular tumor board (MTB) in general and according to ESCAT. We included 1226 patients with recurrent and/or metastatic cancer presented at the MTB from 2018 to 2022. Clinical and demographic data collected included age, gender, type of specimen, tumor type, number of prior treatments received, techniques used for molecular analyses, GAs identified, MTB recommendations, and inclusion or not into a clinical trial. The clinical endpoints collected were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), and were correlated with ESCAT. Successful molecular profiling was carried out in 895 of 1226 (73%) patients. Actionable GAs were found in 595 (49%) patients, and 206 (17%) patients were oriented to matched therapies. Eventually, 101 (8%) patients received a matched therapy. For these patients, PFS and OS were significantly longer for GAs classified as ESCAT tiers I/II, compared with tiers III/IV (P = 0.009 and P = 0.014, respectively). Detection of actionable GAs through MTB molecular screening enabled to treat 8% of patients with matched therapy. Patients treated with matched therapy based on ESCAT tiers I/II had statistically longer PFS and OS, compared with ESCAT tiers III/IV.

11 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DGDavid Gentien
David Gentien
ESElnaz Saberi-Ansari
Elnaz Saberi-Ansari
NSNicolas Servant
Nicolas Servant
AJAriane Jolly
Ariane Jolly
PGPierre de la Grange
Pierre de la Grange
EHEmilie Henry
Emilie Henry
Uveal Melanoma (UM) is a rare cancer resulting from transformation of melanocytes residing in the uveal tract. Integrative analysis has identified four molecular and clinical subsets in UM. To improve our molecular understanding of UM we performed extensive multi-omics characterization comparing two aggressive UM patient-derived xenograft models with normal choroidal melanocytes, including DNA optical mapping, specific histone modifications, and DNA topology analysis by Hi-C. Our gene expression and cytogenetic analyses suggest that genomic instability is a hallmark of UM. We also identified a recurrent deletion in the BAP1 promoter resulting in loss of expression and associated with high risk of metastases in UM patients. Hi-C revealed chromatin topology changes associated with up-regulation of PRAME , an independent prognostic biomarker in UM and potential therapeutic target. Our findings illustrate how multi-omics approaches can improve the understanding of tumorigenesis and reveals two novel mechanisms of gene expression dysregulation in UM.

10 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RGRamón García-Areas
Ramón García-Areas
EGElodie Girard
Elodie Girard
HLHamza Lasla
Hamza Lasla
VRVirginie Raynal
Virginie Raynal
APAmit Kumar Pandey
Amit Kumar Pandey
TDThierry Dubois
Thierry Dubois
Aberrant activation of the Wnt signaling pathway in triple-negative breast cancer (TNBC) is linked to treatment resistance and recurrence, yet its role in tumoral heterogeneity remains unclear. We developed Wnt reporter cell lines from two mesenchymal TNBC models (MDA-MB-231 and MDA-MB-436) using a Tcf/Lef-eGFP vector and observed intra- and inter-tumoral variation in Wnt activity. Paired Wnt-positive and Wnt-negative TNBC cell lines were established and profiled by RNA-Seq. Integrative analyses revealed that Wnt-positive cells consistently upregulate genes involved in epithelial-to- mesenchymal transition, inflammation (e.g., IL6/JAK/STAT3, TNFα via NF-κB), and extracellular matrix remodeling. A 55-gene Wnt signature common to both nutrient conditions captured these features. Wnt-related gene sets were also enriched in the Mesenchymal-like Immune-Altered subtype of 699 primary TNBC tumors. These findings highlight the role of basal Wnt activity in driving pro-tumorigenic transcriptional programs in TNBC and provide new insight into its contribution to subtype-specific disease features.

14 February 2022 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
Fabien ForestFabien Forest
Fabien Forest
JMJulien Masliah-Planchon
Julien Masliah-Planchon
CBClaire Berger
Claire Berger
FPFabienne Prieur
Fabienne Prieur
EGElodie Girard
Elodie Girard
CGCatherine Godfraind
Catherine Godfraind

12 June 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
SSSuzy Marie E. Scholl
Suzy Marie E. Scholl
ENElaine Del Nery
Elaine Del Nery
PGPierre Gestraud
Pierre Gestraud
MHMaral Halladjian
Maral Halladjian
EGElodie Girard
Elodie Girard
MKMaud Kamal
Maud Kamal
Introduction: Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to commonly used drugs, aiming to identify novel biomarkers of treatment response or resistance. Material and Methods: Twenty cell lines (CLs) were characterized for HPV type, for genetic alterations, and protein expression profiles. Pharmacoprofiling in 10 selected CLs was carried out against 34 drugs used in the clinic, assessing drug concentrations needed to reach half maximal inhibitory concentration (IC50) in nanomolar and micromolar ranges. Subtractive bioinformatics analyses aimed to identify genetic alterations (609 genes of clinical interest), associated with CL drug resistance or on the contrary with synthetic lethality. Results: Despite a small sample size, genetic alteration frequencies and types of CCCLs were in line with those in clinical samples, except for the detection of a higher frequencyin specific genetic alterations such as NBPF1 and STK11 in CLs. Pharmacological screening identified drugs exhibiting therapeutic activity in most CLs while others were highly selective. Bioinformatics analyses suggested, loss‐of‐function (LoF) alterations in PAPBC3 in CLs sensitive to microtubule interfering agentsin addition to 50 variably present alterations in the microtubule pathway. LoF alterations in CSMD3, OBSCN, ZNF 717, ALPK2, CLDND1, GTF3A, NLRP1, SI, and TRIM66 were associated with Epigenetic acting drug activity and LoF of OSBPL1A with Eprenetapopt (APR‐246) activity. Drug synergistic effects were observed with certain drug combinations. Conclusion: This paper reports genetic variants in 20 CLs as well as the results of the assessment on whether those variants may help predict response or resistance to certain drug families. With a few exceptions, genetic alteration frequency in CCCLs, conducted in the same analytical batches, compares favorably with published patient data. Results need confirmation in independent larger studies both in CLs and in clinical settings.

29 April 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
LFLaura Fertitta
Laura Fertitta
FCFanny Coulpier
Fanny Coulpier
LOLayna Oubrou
Layna Oubrou
NONicolas Ortonne
Nicolas Ortonne
EPEric Pasmant
Eric Pasmant
PTPiotr Topilko
Piotr Topilko